Torin 2 is a tricyclic benzonaphthyridinone that inhibits mTORC1/2 and exhibits anticancer activity. In hepatocellular carcinoma cells, torin 2 inhibits cell growth and survival and induces apoptosis and autophagy. In acute lymphoblastic leukemia (ALL) cells, torin 2 induces G0/G1 phase cell cycle arrest and inhibits cell growth.
| Cas No. | 1223001-51-1 |
|---|---|
| Purity | ≥98% |
| Formula | C24H15F3N4O |
| Formula Wt. | 432.41 |
| IUPAC Name | 9-(6-Amino-3-pyridinyl)-1-[3-(trifluoromethyl)phenyl]benzo[h][1,6]naphthyridin-2(1H)-one |
| Solubility | 20mM in DMSO, insoluble in H2O and ethanol |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Wang C, Wang X, Su Z, et al. The novel mTOR inhibitor Torin-2 induces autophagy and downregulates the expression of UHRF1 to suppress hepatocarcinoma cell growth. Oncol Rep. 2015 Oct;34(4):1708-16. PMID: 26239364.
Simioni C, Cani A, Martelli AM, et al. Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. Oncotarget. 2014 Oct 30;5(20):10034-47. PMID: 25296981.
